



BioCorporate profile downloaded from - <http://www.bioportfolio.com> on Tuesday, November 24, 2009

ZelleRx Corporation

[View the current ZelleRx Corporation Page on BioPortfolio.com](http://www.bioportfolio.com/biocorporate/32231-ZelleRx+Corporation.html)

(<http://www.bioportfolio.com/biocorporate/32231-ZelleRx+Corporation.html>)

Contact Details:

**400 North Noble, Suite 100
Chicago
Illinois
60622
United States of America**

Tel: 312-243-5200
Fax: 312-275-7364
Email: info@zellerx.com

ZelleRx is committed to being the industry leader in the development of natural killer cell therapies through products derived from its proprietary NK-92 cell line. These natural killer cells have been shown to seek and destroy cancer tumor cells within the human body. In recent years, the use of NK cells for cancer therapy has emerged as a leading novel approach. NK cells were originally identified at the National Cancer Institute in the laboratories of Ronald Herberman, M.D., a member of the ZelleRx Board of Directors. The first product being developed by ZelleRx is ZRx101, based on the unmodified NK-92 cell line. ZRx101 has been demonstrated in numerous preclinical studies to be effective at killing a broad scope of cancers. ZelleRx is currently finishing Phase I clinical trials for ZRx101.

ZelleRx is also developing a pipeline of targeted products against specific cancers – ZRx102 and ZRx103. Each of these development products is based on variants of the NK-92 cell line, selected as a result of research and animal model evaluations that have been conducted in medical institutions.

The name “ZelleRx” derives from “Zelle,” the German word for cell and “Rx,” a shorthand notation for dosage. The combination of these two words defines ZelleRx's focus on developing cellular products for the treatment of cancer.

Press Releases on ZelleRx Corporation:

[New Science Program
Teaches High School
Students About Blood
and Career
Opportunities in the
Field of Hematology](#)

23rd November,
2009

American Society of
Hematology

WASHINGTON, Nov. 23
/PRNewswire-USNewswire/ -- The
American Society of Hematology
(ASH) and Scholastic, the global
children's publishing,
education, and media company, are
launching "Explore

DURECT to Present at the 21st Annual Piper Jaffray Health Care Conference	23rd November, 2009	DURECT Corporation	CUPERTINO, Calif., Nov. 23 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today that Matt Hogan, Chief Financial Officer, and Joe Stauffer, Chief Medical Officer, will be
DaVita Launches Minority Bank Initiative with \$1 Million Investment in Industrial Bank of Washington, D.C. to Support Underserved Communities	23rd November, 2009	DaVita Inc.	Partnerships with Minority Banks in Washington D.C., New York City, Los Angeles and Columbia, S.C. Intended to Spur Economic Growth and Revitalization WASHINGTON, Nov. 23 /PRNewswire-USNewswire/ --
Anthem Blue Cross and Blue Shield in Wisconsin Earns NCQA Accreditation Status of Excellent	23rd November, 2009	Anthem Blue Cross Blue Shield in Wisconsin	MILWAUKEE, Nov. 23 /PRNewswire/ -- Anthem Blue Cross and Blue Shield (Anthem) today announced that its Wisconsin plan has earned the accreditation status of Excellent from the National Committee for
Reportlinker Adds India Dental Devices Investment Opportunities, Analysis and Forecasts to 2015	23rd November, 2009	Reportlinker	NEW YORK, Nov. 23 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue. India Dental Devices Investment Opportunities, Analysis and Forecasts to

BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

